HER2 amplification leads to resistance to EGFR-TKIs in NSCLC (30), and HER2 mutations exhibit similar effects (220), with HER2D16 leading to osimertinib resistance via the Src non-dependent pathway (221). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.